SLN•benzinga•
Silence Therapeutics Gets FDA Fast Track Status For Blood Cancer Candidate
Summary
Silence Therapeutics (NASDAQ: SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera (PV).
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga